

January 14, 2016



# Eyegate Pharmaceuticals to Present at the Noble Financial Capital Markets' 12th Annual Investor Conference

WALTHAM, Mass., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (NASDAQ:EYEGW) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced Stephen From, President & Chief Executive Officer of EyeGate, is scheduled to present at the Noble Financial Capital Markets' 12<sup>th</sup> Annual Conference, being held January 17-20, 2016 in Sandpiper Bay, Florida.

Details of the presentation are as follows:

	Noble Financial Capital
<b>Conference:</b>	Markets
<b>Date:</b>	Monday, January 18th, 2016
<b>Time:</b>	11:00 a.m. ET
<b>Room:</b>	Room 1

Following the Conference on January 22, 2016, a high-definition video webcast of EyeGate's presentation and a copy of the presentation materials will be available on the Company's web site [www.eyegatepharma.com](http://www.eyegatepharma.com), or as part of a complete catalog of presentations available at Noble Financial websites: [www.noblefcm.com](http://www.noblefcm.com), or [www.nobleconference.com](http://www.nobleconference.com). You will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate. The webcast and presentation will be archived on the company's website and on the Noble websites for 90 days following the event.

Investors attending the conference who would like to schedule a 1-on-1 meeting with EyeGate's management may do so by contacting Joseph Green of The Ruth Group at [jgreen@theruthgroup.com](mailto:jgreen@theruthgroup.com).

## About EyeGate:

EyeGate is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. EGP-437, the Company's first and only product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through EyeGate's proprietary innovative drug delivery system, the EyeGate® II Delivery System. For more information, please visit [www.EyeGatePharma.com](http://www.EyeGatePharma.com).

## Safe Harbor Statement:

*Some of the statements in this press release are "forward-looking" and are made pursuant*

*to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will,” or words of similar meaning and include, but are not limited to, statements regarding the outlook for our future business and financial performance. Forward-looking statements are based on our current expectations and assumptions, which are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Actual outcomes and results may differ materially from those in the forward-looking statements due to global political, economic, business, competitive, market, regulatory and other factors and risks, including, among other things, certain risk factors described under the heading “Risk Factors” contained in our Annual Report on Form 10-K filed with the SEC on March 31, 2015, or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. EyeGate expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.*

Contact:

Lee Roth / Joseph Green

The Ruth Group for Eyegate Pharmaceuticals

646-536-7012 / 7013

[lroth@theruthgroup.com](mailto:lroth@theruthgroup.com) / [jgreen@theruthgroup.com](mailto:jgreen@theruthgroup.com)



Source: Eyegate Pharmaceuticals, Inc.